FDA approves Olumiant for teens with severe alopecia

FDA approves baricitinib for adolescents with severe alopecia areata

The FDA has expanded the indication for baricitinib (Olumiant), a once-daily oral JAK inhibitor, to include adolescents aged 12 and older with severe alopecia areata. This marks the second JAK inhibitor treatment approved for adolescents with the condition.